Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
0.9950
+0.0236 (2.43%)
At close: Jun 18, 2026, 4:00 PM EDT
0.9901
-0.0049 (-0.49%)
After-hours: Jun 18, 2026, 7:52 PM EDT
Cocrystal Pharma Revenue
Cocrystal Pharma had revenue of $225.00K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $225.00K.
Revenue (ttm)
$225.00K
Revenue Growth
n/a
P/S Ratio
60.97
Revenue / Employee
$22,500
Employees
10
Market Cap
13.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 2.01M | -4.55M | -69.32% |
| Dec 31, 2019 | 6.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 78.00K | 69.00K | 766.67% |
| Dec 31, 2014 | 9.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 12.61M | -2.65M | -17.36% |
| Dec 31, 2010 | 15.25M | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Traws Pharma | 2.73M |
| OSR Holdings | 2.63M |
| Cyclerion Therapeutics | 1.99M |
| BioLineRx | 1.40M |
| CytoMed Therapeutics | 669.28K |
COCP News
- 15 days ago - Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds - TheFly
- 15 days ago - Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer - GlobeNewsWire
- 23 days ago - Cocrystal Pharma announces discovery of pan-viral inhibitors targeting viruses - TheFly
- 23 days ago - Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza - GlobeNewsWire
- 4 weeks ago - Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 7 weeks ago - Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection - GlobeNewsWire
- 2 months ago - Cocrystal Pharma files $150M mixed securities shelf - TheFly
- 2 months ago - Cocrystal Pharma receives FDA Fast Track designation for CDI-988 - TheFly